Black Diamond Therapeutics (NASDAQ:BDTX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX) in a report released on Tuesday, Benzinga reports. HC Wainwright currently has a $11.00 target price on the stock.

A number of other research firms also recently commented on BDTX. Piper Sandler lifted their price target on Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an overweight rating in a research note on Monday. Raymond James began coverage on Black Diamond Therapeutics in a report on Wednesday, July 31st. They issued an outperform rating and a $20.00 price target for the company. Finally, Wedbush reaffirmed an outperform rating and issued a $16.00 price objective on shares of Black Diamond Therapeutics in a report on Tuesday, September 10th.

Black Diamond Therapeutics Trading Up 1.8 %

Black Diamond Therapeutics stock opened at $4.58 on Tuesday. Black Diamond Therapeutics has a 52 week low of $1.62 and a 52 week high of $7.66. The stock has a market cap of $257.64 million, a P/E ratio of -2.76 and a beta of 2.49. The stock has a 50 day moving average of $5.63 and a 200-day moving average of $5.36.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities analysts predict that Black Diamond Therapeutics will post -1.4 earnings per share for the current fiscal year.

Institutional Trading of Black Diamond Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in BDTX. Susquehanna Fundamental Investments LLC acquired a new position in Black Diamond Therapeutics during the 1st quarter valued at approximately $82,000. SG Americas Securities LLC bought a new stake in Black Diamond Therapeutics in the second quarter valued at $108,000. Jump Financial LLC boosted its holdings in shares of Black Diamond Therapeutics by 245.0% during the fourth quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock valued at $109,000 after acquiring an additional 27,616 shares during the period. Algert Global LLC bought a new position in shares of Black Diamond Therapeutics during the second quarter worth about $133,000. Finally, Pale Fire Capital SE acquired a new stake in shares of Black Diamond Therapeutics in the 4th quarter worth about $144,000. 95.47% of the stock is currently owned by institutional investors and hedge funds.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.